<?xml version="1.0" encoding="UTF-8"?>
<p>Benefit risk analysis can be adapted considering the R&amp;D phase of the MD or ATMP. Indeed, risks can be detected in non-clinical phase and continue throughout the development of the MD or ATMP in order to prevent and minimise risks when possible [
 <xref rid="B127-materials-13-04532" ref-type="bibr">127</xref>]. 
</p>
